MicroRNA-221 and -222 pathway controls melanoma progression

References

• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new target therapy. Nature445, 851–857 (2007).
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC. Melanoma. N. Engl. J. Med.355, 51–65 (2006).
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lee CS, Scolyer RA et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol.20, 416–426 (2007).
   PubMed Web of Science ®Google Scholar
• Dhomen N, Marais R. New insight into BRAF mutation in cancer. Curr. Opin. Genet. Dev.17, 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Houben R, Becker JC. Molecular mechanisms in melanoma. N. Engl. J. Med.355, 1395–1396 (2006).
   PubMedGoogle Scholar
• Clark WH, Elder DE, Guerry D 4th, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesion of superficial spreading and nodular melanoma. Hum. Pathol.15, 1147–1165 (1984).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer6, 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Yan X, Chao T, Tu Ket al. Improving the prediction of human microRNA target genes by using ensemble algorithm. EBS Lett.581, 1587–1593 (2007).
   PubMed Web of Science ®Google Scholar
• Molnár V, Tamási V, Bakos B, Wiener Z, Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin. Cancer Biol.18, 111–122 (2008).
   PubMed Web of Science ®Google Scholar
• Worley LA, Long MD, Onken MD, Harbour JW. MicroRNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res.18, 184–190 (2008).
   PubMed Web of Science ®Google Scholar
• Bemis LT, Chen R, Amato CM et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cells. Cancer Res.68, 1362–1368 (2008).
   PubMed Web of Science ®Google Scholar
• Shultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res.18, 549–557 (2008).
   PubMed Web of Science ®Google Scholar
• Felicetti F, Errico MC, Bottero L et al. The promyelocytic leukemia zinc finger–microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res.68, 2745–2754 (2008).
   PubMed Web of Science ®Google Scholar
• Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene26, 4442–4452 (2007).
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA102, 19075–19080 (2005).
   PubMed Web of Science ®Google Scholar
• le Sage C, Nagel R, Egan DA et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J.26, 3699–3708 (2007).
   PubMed Web of Science ®Google Scholar
• Galardi S, Mercatelli N, Giorda E et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J. Biol. Chem.282, 23716–23724 (2007).
   PubMed Web of Science ®Google Scholar
• Medina R, Zaidi SK, Liu CG et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res.68, 2773–2780 (2008).
   PubMed Web of Science ®Google Scholar
• Felli N, Fontana L, Pelosi E et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl Acad. Sci. USA102, 18081–18086 (2005).
   PubMed Web of Science ®Google Scholar
• Kasamatsu S, Hachiya A, Higuchi Ket al. Production of the soluble form of KIT, s-KIT, abolishes stem cell factor-induced melanogenesis in human melanocytes. J. Invest. Dermatol.128, 1763–1772 (2008).
   PubMed Web of Science ®Google Scholar
• Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem. Biophys. Res. Commun.354, 830–835 (2007).
   PubMed Web of Science ®Google Scholar
• Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res.79(4), 581–588 (2008).
   PubMed Web of Science ®Google Scholar
• Li W, Sanki A, Karim RZ et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology38, 287–301 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell120, 15–20 (2005).
   PubMed Web of Science ®Google Scholar
• Krek AD, Grun D, Poy MN et al. Combinatorial microRNA target predictions. Nat. Genet.37, 495–500 (2005).
   PubMed Web of Science ®Google Scholar
• Kotoshiba S, Kamura T, Hara T, Ishida N, Nakayama KI. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J. Biol. Chem.280, 17694–17700 (2005).
   PubMed Web of Science ®Google Scholar
• Delmas C, Aragou N, Poussard S, Cottin P, Darbon JM, Manenti S. MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells. Requirement of p27Kip1 nuclear export. J. Biol. Chem.278, 12443–11251 (2003).
   PubMed Web of Science ®Google Scholar
• Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell9, 75–76 (2006).
   PubMed Web of Science ®Google Scholar
• Fornari F, Gramantieri L, Ferracin M et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene27(43), 5651–5661 (2008).
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature438, 685–689 (2005).
   PubMed Web of Science ®Google Scholar
• Carè A, Catalucci D, Felicetti F et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med.13, 613–618 (2007).
   PubMed Web of Science ®Google Scholar
• Krutzfeld J, Kuwajima S, Braich R et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res.35, 2885–2892 (2007).
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol.23, 709–717 (2005).
   PubMed Web of Science ®Google Scholar
• Hu YX, Watanabe H, Li P et al. An immunohistochemical analysis of p27 expression in human pancreatic carcinomas. Pancreas21, 226–230 (2000).
   PubMed Web of Science ®Google Scholar
• Fletcher JA, Rubin BP. KIT mutations in GIST. Curr. Opin. Genet. Dev.17, 3–7 (2007).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Saenger YM. Current topics in melanoma. Curr. Opin. Oncol.19, 116–120 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev. Biol.302, 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Tuddenham L, Wheeler G, Ntounia-Fousara S et al. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett.580, 4214–4217 (2006).
   PubMed Web of Science ®Google Scholar
• Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell9, 435–443 (2006).
   PubMed Web of Science ®Google Scholar